Cargando…

Author Correction: The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort

Detalles Bibliográficos
Autores principales:	Su, Yung-Yeh, Chiang, Nai-Jung, Tsai, Hui-Jen, Yen, Chia-Jui, Shan, Yan‐Shen, Chen, Li‐Tzong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666201/ https://www.ncbi.nlm.nih.gov/pubmed/33188263 http://dx.doi.org/10.1038/s41598-020-77250-4

Ejemplares similares

The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
por: Su, Yung-Yeh, et al.
Publicado: (2020)

Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study
por: Chiu, Tai-Jan, et al.
Publicado: (2021)

Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study
por: Su, Yung-Yeh, et al.
Publicado: (2022)

Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI‐1 study
por: Bang, Yung‐Jue, et al.
Publicado: (2019)

Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
por: Frampton, James E.
Publicado: (2020)

Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022)

Correction to: Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
por: Frampton, James E.
Publicado: (2020)

Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan
por: Koeller, Jim, et al.
Publicado: (2020)

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2023)

Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study
por: Gupta, Amol, et al.
Publicado: (2023)

Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan
por: Yu, Kenneth H., et al.
Publicado: (2021)

A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors
por: Chiang, Nai-Jung, et al.
Publicado: (2016)

Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy
por: Bang, Kyunghye, et al.
Publicado: (2021)

Percutaneous Computed Tomography-Guided Coaxial Core Biopsy for the Diagnosis of Pancreatic Tumors
por: Su, Yung-Yeh, et al.
Publicado: (2019)

A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma
por: Singhal, Ruchi, et al.
Publicado: (2023)

A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium
por: Verbruggen, Lise, et al.
Publicado: (2023)

Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer
por: Barbier, Sandrine, et al.
Publicado: (2023)

Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer
por: Chen, Li-Tzong, et al.
Publicado: (2019)

Author Correction: Investigating the relationship between district-level socioeconomic status and individual obesity in Taiwanese adolescents: A large-scale cross-sectional analysis
por: Ni, Ying-Lien, et al.
Publicado: (2020)

Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group
por: Yoo, Changhoon, et al.
Publicado: (2019)

Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives
por: Woo, Wonhee, et al.
Publicado: (2019)

Author Correction: Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma
por: Nik, Maryam Ebrahimi, et al.
Publicado: (2020)

Author Correction: Relationship between body mass index and renal function deterioration among the Taiwanese chronic kidney disease population
por: Chang, Tian-Jong, et al.
Publicado: (2020)

Author Correction: Genetic dissection of clonal lineage relationships with hydroxytamoxifen liposomes
por: Ransom, Ryan C., et al.
Publicado: (2018)

Author Correction: The role of tumor model in magnetic targeting of magnetosomes and ultramagnetic liposomes
por: Curcio, Alberto, et al.
Publicado: (2023)

Author Correction: Interplay of protein corona and immune cells controls blood residency of liposomes
por: Giulimondi, Francesca, et al.
Publicado: (2020)

Author Correction: Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population
por: Zheng, Cai-Mei, et al.
Publicado: (2020)

Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States
por: Barzi, Afsaneh, et al.
Publicado: (2020)

Author Correction: Generation of convergent light beams by using surface plasmon locked Smith-Purcell radiation
por: Lai, Yi-Chieh, et al.
Publicado: (2017)

Author Correction: The State of the World’s Beaches
por: Luijendijk, Arjen, et al.
Publicado: (2018)

Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan
por: Chen, Chia-Yu, et al.
Publicado: (2020)

Author Correction: Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment
por: Werba, Gregor, et al.
Publicado: (2023)

Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer
por: Su, Yung-Yeh, et al.
Publicado: (2023)

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer
por: Adiwijaya, BS, et al.
Publicado: (2017)

Author Correction: A matched case-control study in Taiwan to evaluate potential risk factors for prostate cancer
por: Chang, Heng-Jui, et al.
Publicado: (2023)

A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid
por: Kieler, Markus, et al.
Publicado: (2019)

Author Correction: Liposomal delivery of azithromycin enhances its immunotherapeutic efficacy and reduces toxicity in myocardial infarction
por: Al‑Darraji, Ahmed, et al.
Publicado: (2021)

Author Correction: Mutations in VP1 and 5′-UTR affect enterovirus 71 virulence
por: Chang, Ching-Kun, et al.
Publicado: (2018)

ASO Author Reflections: Surgical Predictors for Survival in Patients Undergoing Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma
por: Korrel, Maarten, et al.
Publicado: (2020)

Mast cells in pancreatic ductal adenocarcinoma
por: Chang, David Z.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_cd6djepuf7cp84up7vl70154e4